Shares digital

Life sciences group Celsis International (CEL) has reported strong H2 trading, in line with expectations, sending its shares up 6% to 182.5p. The Rapid Detection division is benefiting from strong demand across all geographical regions and sectors of the business, while its Vitro Technologies is expected to continue to enjoy solid growth as it strengthens its position in North America and the EU. However, its Analytical Services business is likely to complete the full year slightly down from the year before.

Shares says: Overall encouraging growth and a positive outlook. RR